🧪 Navamedic to Acquire dne pharma Business for Up to NOK 225 million: A Bold Play in Specialty Pharma

Navamedic ASA (OSE: NAVA), a Nordic-focused pharmaceutical player, announced today it has signed an agreement to acquire the business operations of Norwegian-based dne pharma for a total consideration of up to NOK 225 million.

🔍 What the Deal Involves

• Transaction Scope: Navamedic is set to acquire dne pharma’s entire business operations in Norway, encompassing all assets, market authorizations, and established client contracts.
• Price Structure: The deal is composed of an upfront payment plus potential earn-outs, with the total deal value capped at NOK 225 million (~USD 20 million).
• Finalization Timeline: The acquisition is expected to close in Q3 2025, pending regulatory approvals and customary closing conditions.

📈 Strategic Rationale: Strengthening Core Specialties

This acquisition aligns perfectly with Navamedic’s focused M&A strategy, which emphasizes in-licensing and acquiring firms in niche areas like obesity, neurology, medical nutrition, urology, and pain management .

Why dne pharma makes sense:

• They already have a reputable presence in addiction medicine, such as their Ventizolve® nasal naloxone product—a lifesaving treatment for opioid overdose.
• The business brings in existing revenue streams, high-quality employee expertise, and valuable regulatory approvals—offering both immediate contribution and long-term growth potential.

🚀 Boosting Navamedic’s Growth Trajectory

The deal is set to inject:

1. New revenue gear from addiction and potential adjacent therapy segments.
2. Expanded product capabilities, especially in nasal delivery—a growing and important segment.
3. Cultural fit and know-how, as dne pharma’s team brings local leadership in their therapeutic focus areas.
4. Potential for North European expansion, reinforcing Navamedic’s goal to become a NOK 1 billion revenue company through a mix of organic growth and targeted acquisitions.

📊 Financial & Strategic Context

• Recent performance: Navamedic delivered NOK 132 million in Q1 2025 revenues (+9.2% YoY), and an EBITDA of NOK 12.8 million—a 50% jump YoY .
• The company has been proactive: from antibiotics tender wins to expanding consumer health with products like Eroxon®, Modifast, Absolut Torr, and medical nutrition items.
• M&A credentials: Navamedic has a strong track record, previously acquiring Impolin (2022), Sensidose (Parkinson’s therapy, 2023), and now targeting dne pharma to further bolster its therapeutic footprint